medical

AbbVie Inc. Announces that SKYRIZI™ Met Both Primary and All Ranked Secondary Endpoints

AbbVie Inc. Announces that SKYRIZI™ Met Both Primary and All Ranked Secondary Endpoints

AbbVie Inc. (NYSE: ABBV) announced Tuesday that SKYRIZI™ met both primary and all ranked secondary endpoints, which includes superiority at week 52, versus Cosentyx® in a head-to-head Phase 3 study. SKYRIZI showed significantly higher rate..

Gilead Sciences Announced Licensing of Portfolio of HIV Antibodies

Gilead Sciences Announced Licensing of Portfolio of HIV Antibodies

Gilead Sciences, Inc. (NASDAQ: GILD) announced Thursday that it has licensed The Rockefeller University’s portfolio of broadly neutralizing antibodies (bNAbs) against HIV, including the two clinical-stage agents 3BNC117 and 10-1074. These inve..